However, in some cases, ligand binding to MGL might be also associated with tumor evasion of the immune system through the suppression of immune cell activation and/or the promotion of immune tolerance, which means that the immune system may not recognize the cancer cells as effectively as it should. Here, CLEC10A is linked to neoplasm.